Ran Nussbaum - Jun 8, 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jun 8, 2022
Transactions value $
$0
Form type
4
Date filed
6/10/2022, 03:36 PM
Previous filing
Feb 28, 2023
Next filing
Jun 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right to buy) Award $0 +6.82K $0.00 6.82K Jun 8, 2022 Ordinary Shares 6.82K $7.06 by Pontifax (Israel) III Limited Partnership F1
transaction URGN Stock Option (right to buy) Award $0 +3.18K $0.00 3.18K Jun 8, 2022 Ordinary Shares 3.18K $7.06 By Pontifax Cayman III Limited Partnership F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year.